20 Nov

How Could Investing in PBE Affect Your Portfolio?

WRITTEN BY Ivan Kading

Underperformer

The PowerShares Dynamic Biotechnology & Genome Portfolio ETF (PBE) seeks to follow the Dynamic Biotech & Genome Intellidex Index. Biotechnology stocks are highly risky and sensitive to market movement. Due to the poor performance of the market as a whole, PBE has underperformed with a YTD (year-to-date) return of 1.8%. PBE’s annualized return since inception is 12.7%, showing its strong performance over the years. PBE’s top five holdings are Regeneron Pharmaceuticals (REGN), Amgen (AMGN), Gilead Sciences (GILD), Alexion Pharmaceuticals (ALXN) and Incyte (INCY).

How Could Investing in PBE Affect Your Portfolio?

Low returns, accelerated recovery

The above chart compares the YTD performance of a portfolio of SPY and PBE. Due to PBE’s weak performance, the portfolio’s price movement has lagged behind the market in all past quarters. However, in October 2015, the portfolio recovered significantly, which can be attributed to the strong earnings of the biotechnology sector in 3Q15. As of November 20, 2015, the YTD return of the combined portfolio is 2.6%, less than the market YTD return of 3.0%.

Conclusion

PBE’s pure equity nature coupled with its biotechnology portfolio makes it one of the riskiest smart beta ETFs in the market. High-risk assets are generally more rewarding than medium-to-low risk assets, but are also more vulnerable to a crash. Investors should identify their risk-taking capabilities before investing in such funds.

Latest articles

US crude oil production has more than doubled since 2009 and grew by 1.1% over the last year. Currently, there are 133 operable refineries in the US.

The cannabis industry is fighting against the ongoing US-China trade war and recessionary worries, which have hurt valuations across the global market.

Higher revenues, increased ticket prices, and lower fuel costs are likely to drive American Airlines' Q3 earnings higher despite its Boeing MAX woes.

HEXO plans to report its Q4 earnings before the market opens on October 24. October has been tough for Hexo, with its stock falling 31.2% as of October 18.

Today, Advanced Micro Devices (AMD) rose 4% to over $32, making it one of the top Nasdaq gainers. Morgan Stanley raised its price target for AMD stock.

Early in 2019, President Donald Trump warned that China could overtake the US as a global power. He vowed that this would not happen under his leadership.